Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XYLOCAINE vs ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.
Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.
Local anesthesia for infiltration, nerve block, epidural, spinal, and topical use,Treatment of acute ventricular arrhythmias (e.g., during cardiac surgery or myocardial infarction),Off-label: treatment of status epilepticus, neuropathic pain, and tinnitus
Local anesthesia for dental procedures requiring infiltration or nerve block anesthesia
1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 m L.
For local anesthesia: 1-5 m L of 2% solution (20 mg/m L) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).
Terminal elimination half-life is approximately 1.5 to 2 hours in adults, prolonged to 2-3 hours in patients with hepatic impairment, and may exceed 5 hours in neonates or patients with heart failure.
Articaine: approximately 1-2 hours (terminal half-life). Levonordefrin: not separately reported; vasoconstrictor effect duration supports anesthetic action. Clinical context: half-life is short, reflecting rapid metabolism by plasma esterases; clinical duration of anesthesia is prolonged by levonordefrin.
Primarily hepatic via CYP1A2 and CYP3A4 to active metabolites (monoethylglycinexylidide and glycinexylidide).
Articaine is metabolized primarily by plasma esterases (butyrylcholinesterase) to its inactive metabolite articainic acid; levonordefrin is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Hepatic metabolism (primarily by CYP1A2 and CYP3A4) to metabolites, mainly monoethylglycinexylidide (MEGX) and glycinexylidide (GX); less than 10% excreted unchanged in urine. Renal excretion of metabolites: MEGX (70-80%) and GX (10-20%). Biliary/fecal elimination is minimal.
Renal: primarily as metabolites (hydroxy derivatives) and unchanged drug; approximately 90% eliminated in urine as metabolites, <5% unchanged. Biliary/fecal: minor, <10%.
Approximately 65-70% bound to plasma proteins, primarily alpha-1-acid glycoprotein (AAG) and, to a lesser extent, albumin.
Articaine: approximately 70-80% bound, primarily to albumin. Levonordefrin: not reported.
Volume of distribution (Vd) is 0.8-1.3 L/kg. Higher Vd in neonates (up to 2.75 L/kg) indicates extensive tissue distribution.
Articaine: Vd ~1.0 L/kg. Clinical meaning: moderate distribution into total body water, consistent with local anesthetic profile.
Intravenous: 100%; Intramuscular: 70-90%; Epidural: near 100%; Topical: variable and low due to systemic absorption, typically <10%; Oral: less than 30% due to extensive first-pass metabolism.
Not applicable for local anesthetic; administered parenterally (infiltration/block). By submucosal injection:100% systemically available (though redistributes locally).
No adjustment required for GFR >30 m L/min; avoid in severe renal impairment (GFR <30 m L/min) due to risk of accumulation.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of metabolites.
Child-Pugh A/B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B: Consider 50% dose reduction. Child-Pugh C: Avoid use or reduce dose by 75%; monitor for systemic toxicity.
1-2 mg/kg (max 4.5 mg/kg) local infiltration; adjust based on lean body weight.
Weight-based: 0.5-1.0 mg/kg per injection site, not to exceed 3.5 mg/kg total; maximum single dose 200 mg. Adjust for age and body weight; use lower concentrations (1:100,000 epinephrine equivalent).
Reduce dose by 40-50% due to decreased clearance and increased sensitivity to CNS/cardiac effects.
Reduce dose by 20-50% due to increased risk of cardiovascular and central nervous system effects; consider lower concentration and slower administration.
None.
None
Risk of local anesthetic systemic toxicity (LAST) including CNS and cardiovascular effects, especially with inadvertent intravascular injection or high doses,Use with caution in patients with hepatic impairment, severe renal impairment, or hypovolemia,May cause methemoglobinemia, especially in infants,Monitor ECG when used intravenously for arrhythmias
Risk of methemoglobinemia, especially with higher doses, in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or exposure to oxidizing agents,Cardiovascular effects due to levonordefrin, including hypertension, hypotension, tachycardia, and cardiac arrhythmias; use caution in patients with cardiovascular disease, hypertension, or hyperthyroidism,Allergic reactions including anaphylaxis have been reported,Systemic toxicity due to inadvertent intravascular injection; observe proper injection technique,Use caution in patients with impaired liver function or severe renal impairment
Hypersensitivity to lidocaine or amide-type local anesthetics,Stokes-Adams syndrome or severe heart block (for IV antiarrhythmic use),Severe hypotension or cardiogenic shock,Do not use for spinal anesthesia if patient has bleeding disorders or infection at injection site
Hypersensitivity to articaine, levonordefrin, or any component of the formulation,Hypersensitivity to amide-type local anesthetics or sympathomimetic amines,Severe or uncontrolled hypertension,Concurrent use of MAO inhibitors or within 14 days of discontinuation (due to risk of hypertensive crisis)
No clinically significant food interactions reported.
No significant food interactions. Avoid alcohol consumption for at least 24 hours after the procedure as it may increase the risk of bleeding at the injection site.
First trimester: No increased risk of major malformations observed in human studies. Second and third trimesters: Potential for fetal bradycardia and central nervous system depression with high maternal serum levels. Use only if clearly needed.
FDA Pregnancy Category C. First trimester: Limited human data, animal studies suggest risk of fetal cardiovascular abnormalities at high doses. Second/third trimesters: May cause uteroplacental vasoconstriction and fetal hypoxia; avoid use during labor due to risk of maternal hypertension and fetal bradycardia.
Excreted into breast milk in low amounts (M/P ratio approximately 1.0). Considered compatible with breastfeeding; monitor for signs of local anesthetic toxicity in infant.
Minimal excretion into breast milk; M/P ratio unknown. Levonordefrin has low oral bioavailability. Considered compatible with breastfeeding; monitor infant for irritability or tachycardia. Avoid application to nipples.
No standard dose reduction required. Increased plasma volume and protein binding changes may reduce free drug concentration; however, toxicity may occur with standard doses due to altered clearance. Use lowest effective dose and consider patient weight.
No standard dose adjustment required. Use lowest effective dose and shortest duration. Increased plasma volume in pregnancy may slightly reduce peak concentrations, but no dose adjustment is routinely recommended. Avoid use in preeclampsia or severe hypertension.
Use minimum effective dose to avoid systemic toxicity; maximum dose without epinephrine is 4.5 mg/kg (not to exceed 300 mg), with epinephrine (1:200,000) is 7 mg/kg (not to exceed 500 mg). Rapid absorption from highly vascular areas (e.g., intercostal blocks) increases toxicity risk. Always aspirate before injection to prevent intravascular administration. Mixing with epinephrine prolongs duration and reduces peak plasma levels. For pediatric patients, calculate dose based on weight and use reduced concentrations (0.5-1%). In patients with hepatic impairment, reduce dose due to decreased metabolism. Concurrent use with CYP1A2 inhibitors (e.g., fluvoxamine) may increase lidocaine levels.
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a dental anesthetic containing articaine HCl 4% with epinephrine 1:100,000. Levonordefrin is a vasoconstrictor added to prolong local anesthesia. Avoid use in patients with sulfite sensitivity (articaine contains sodium metabisulfite). Maximum dose: 7 mg/kg (articaine) and not to exceed 0.5 mg levonordefrin per appointment. Do not inject into inflamed or infected tissues due to increased absorption. Aspirate before injection to prevent intravascular administration.
Avoid driving or operating machinery until numbness and effects have completely worn off.,Do not eat or drink until sensation returns to prevent biting your tongue or cheek.,Report any signs of allergic reaction (rash, difficulty breathing, swelling) to your healthcare provider immediately.,If you experience dizziness, blurred vision, ringing in ears, or metallic taste, seek emergency care.,Inform your doctor about all medications you take, especially heart medications, anticoagulants, or other local anesthetics.,Numbness and lack of sensation are normal during the procedure; do not scratch or rub the numbed area.
You may experience numbness in your mouth, lips, and tongue for several hours after the injection; avoid eating or drinking hot liquids until sensation returns to prevent burns.,Do not chew on the numb area to avoid accidental injury.,If you have a history of sulfite allergy, inform your dentist before the procedure.,Contact your dentist immediately if you experience severe headache, rapid heartbeat, or difficulty breathing after the injection.,This medication can cause temporary dizziness or lightheadedness; avoid driving until the effects have worn off.
No interactions on record
"Levonordefrin, a vasoconstrictor with beta-agonist activity, may counteract the beta-blocking effects of pindolol, leading to unopposed alpha-adrenergic stimulation and potential hypertensive crisis. Additionally, pindolol's intrinsic sympathomimetic activity (ISA) may interact with levonordefrin, increasing the risk of cardiac arrhythmias and AV block due to conflicting adrenergic signaling. Clinically, this can result in severe hypertension, bradycardia, or heart block, especially in patients with underlying cardiovascular disease."
"Mianserin, a tetracyclic antidepressant with potent alpha-2-adrenergic receptor antagonism, can reduce the vasopressor response to Levonordefrin, a direct-acting alpha-1 adrenergic agonist. This interaction occurs because Mianserin blocks presynaptic alpha-2 receptors, leading to increased norepinephrine release and potential receptor desensitization, as well as possible competitive antagonism at the alpha-1 receptor. Clinically, this may result in diminished efficacy of Levonordefrin when used as a local vasoconstrictor during dental or surgical procedures, potentially leading to inadequate hemostasis or reduced local anesthesia duration."
"Levonordefrin, a sympathomimetic amine with alpha- and beta-adrenergic agonist activity, can enhance the negative dromotropic effect of arotinolol, a non-selective beta-blocker with intrinsic sympathomimetic activity. This results in additive depression of atrioventricular (AV) nodal conduction, potentially leading to prolonged PR interval, second- or third-degree AV block, and symptomatic bradycardia. Clinically, patients may present with dizziness, syncope, or hemodynamic instability, particularly in those with pre-existing conduction abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XYLOCAINE vs ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN, answered by our medical review team.
XYLOCAINE is a Local Anesthetic that works by Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.. ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a Local Anesthetic with Vasoconstrictor that works by Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XYLOCAINE and ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XYLOCAINE is: 1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 m L.. The standard adult dose of ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is: For local anesthesia: 1-5 m L of 2% solution (20 mg/m L) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XYLOCAINE and ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XYLOCAINE is classified as Category C. First trimester: No increased risk of major malformations observed in human studies. Second and third trimesters: Potential for fetal bradycardia and central nervous system depress. ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data, animal studies suggest risk of fetal cardiovascular abnormalities at high doses. Second/third trimesters: May cause u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.